Observation Of Therapeutic Effect About Targeted Therapy On Gastrointestinal Stromal Tumors

Objective:To evaluate the clinical effect of imatinib on unresectable/recurrent/metastatic gastrointestinal stromal tumors(GISTs) or as post-operative adjuvant therapy.Methods:65 patients with GISTs were confinned by pathologic and immunohistological examination.All of these GISTs expressed CD 117. Patients were administered imatinib 400mg/d.45 patients were classified to unresectable/recurrent/metastatic group,20 patients were post-operative adjuvant group.Clinical effect was evaluated through regular examination.Result:All patients were follow-uped.In unresectable/recurrent/metastatic group,45 patients were treated with imatinib immediately after tumor was found to be unresectable/recurrent/metastatic.With a median follow-up of 20 months,2patients was evaluated complete response CR(4.4%),13 patients was evaluated partial response PR(28.9%),14 was evaluated stabilization of disease SD(31.1%),16 was evaluated progression of disease PD(35.6%)..29patients(64.4%) were acquired clinical benefit (disease control).One-year and 2-year progression-flee survival(PFS) were 95.6±3.1%,81.4±6.5%。One-year and 2-year overall survival(OS) were100%,88.8±5.4%.20 patients were treated as post-operative adjuvant therapy.With a median follow-up of 20 months,all patients were free of tumor.One-year and 2-year recurrence-free survival RFS was 100%.Conclusion:Imatinib shows beneficial effects on unresectable/recurrent/metastatic gastrointestinal stromal turnors(GISTs)。That also can decrease the postoperative recurrence rate.